Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $34,916.85 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,503 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $13.95, for a total value of $34,916.85. Following the completion of the transaction, the insider now directly owns 164,363 shares of the company’s stock, valued at approximately $2,292,863.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 1st, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.65, for a total value of $39,171.95.
• On Wednesday, March 13th, Soleil Boughton sold 63,621 shares of Hims & Hers Health stock. The shares were sold at an average price of $15.17, for a total value of $965,130.57.
• On Friday, February 9th, Soleil Boughton sold 4,080 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total value of $40,922.40.
• On Monday, February 12th, Soleil Boughton sold 22,839 shares of Hims & Hers Health stock. The shares were sold at an average price of $10.03, for a total value of $229,075.17.

Hims & Hers Health Stock Performance

NYSE:HIMS traded down $0.26 during mid-day trading on Wednesday, hitting $12.43. 2,231,076 shares of the stock were exchanged, compared to its average volume of 4,688,743. The stock has a market capitalization of $2.66 billion, a price-to-earnings ratio of -114.55 and a beta of 0.91. The firm’s 50-day simple moving average is $13.36 and its 200 day simple moving average is $9.77. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $17.16.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same quarter last year, the company posted ($0.05) EPS. The company’s revenue for the quarter was up 47.4% compared to the same quarter last year. On average, analysts predict that Hims & Hers Health, Inc. will post 0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. CM Wealth Advisors LLC acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at about $25,000. Point72 Middle East FZE acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $29,000. Captrust Financial Advisors lifted its stake in shares of Hims & Hers Health by 1,827.4% in the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock valued at $36,000 after purchasing an additional 6,414 shares during the period. Harbour Investments Inc. lifted its stake in shares of Hims & Hers Health by 427.9% in the 3rd quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock valued at $44,000 after purchasing an additional 5,670 shares during the period. Finally, Belpointe Asset Management LLC bought a new stake in Hims & Hers Health in the 1st quarter valued at about $46,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on HIMS shares. SVB Leerink started coverage on Hims & Hers Health in a research note on Monday, February 26th. They issued a “market perform” rating and a $10.00 price objective for the company. Citigroup increased their price objective on Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target for the company. Piper Sandler raised their target price on Hims & Hers Health from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday, February 27th. Finally, Leerink Partnrs reissued a “market perform” rating on shares of Hims & Hers Health in a report on Monday, February 26th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.85.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.